CCL2 CCL2 3'UTR variant

CCL2 3'UTR — How mRNA Stability Amplifies Vascular Inflammation

Your genome contains not only the code for proteins but also regulatory sequences that control
how long those messages survive inside cells. The rs13900 variant in the 3' untranslated region
of CCL2 — the gene encoding monocyte chemoattractant protein-1 (MCP-1) — is one of these
regulatory switches. Unlike the well-studied promoter variant rs1024611 that controls how much
CCL2 is made in the first place, rs13900 controls how long CCL2 mRNA survives before being
degraded. A longer-lived message means more protein output even if transcription rates are
identical. In individuals who carry the T allele, this post-transcriptional amplification adds
meaningfully to the elevated MCP-1 levels driven by the haplotype partner rs1024611G.

The Mechanism

The rs13900 C-to-T transition in the CCL2 3' UTR alters the local RNA secondary structure in a
way that enhances binding by [Human Antigen R (HuR) | HuR (ELAVL1) is a ubiquitous
RNA-binding protein that stabilizes AU-rich element–containing mRNAs; it is a master regulator
of inflammatory gene expression], an RNA-binding protein that stabilizes mRNAs by protecting
them from nucleolytic degradation. Bioinformatic modeling predicts the T allele forms a stem-loop
structure that presents a better binding surface for HuR than the C allele's predicted open
conformation. Experimental validation confirmed approximately a seven-fold difference in
HuR/antibody complex formation favoring the T allele (p<0.005). Nascent RNA decay experiments
in heterozygous macrophage donors showed that T-allele CCL2 transcripts degrade significantly
more slowly than C-allele transcripts from the same cell, with an overall CCL2 mRNA half-life
of approximately 1.76 hours.

The rs13900T allele also influences mRNA
[translatability | Translatability refers to how efficiently a given mRNA is loaded onto
ribosomes and converted into protein, separate from transcript abundance or stability] —
T-bearing transcripts showed greater association with polysomes, indicating more efficient
protein synthesis per transcript molecule. The combined effect is a double amplification: more
stable transcript × more efficient translation = substantially higher MCP-1 protein output
per cell compared to CC homozygotes.

The Evidence

The foundational demonstration of rs13900's functional significance came from
Pham et al. 2012 — 8 heterozygous donors for allelic expression imbalance (AEI) analysis
| Pham MH et al. The rs1024611 regulatory region polymorphism is associated with CCL2 allelic
expression imbalance. PLoS One. 2012;7(11):e49498.
Using rs13900 as a transcribed proxy for the non-coding rs1024611 promoter variant, they
showed that in every heterozygous individual examined, the T allele was expressed at
significantly higher levels than the C allele (p=0.0009). This established that the G-T
haplotype drives higher CCL2 output in vivo, not just in transfection systems.

The mechanistic detail was resolved by
Akhtar et al. 2026 — 47 healthy individuals screened, 6 heterozygous donors used for
stability analysis | Akhtar et al. The RNA-binding protein HuR modulates the expression of the
disease-linked CCL2 rs1024611G-rs13900T haplotype. eLife. 2026,
who confirmed that HuR preferentially binds T-allele transcripts in vitro (REMSA), ex vivo
(RNA immunoprecipitation from primary macrophages), and that HuR overexpression selectively
increases reporter activity for T-allele but not C-allele constructs (p<0.05). This places
HuR as the molecular bridge between the rs13900 genotype and elevated CCL2 protein output.

The disease relevance of the CCL2-CCR2 signaling axis was directly demonstrated in a murine
arteriogenesis model by
Heil et al. 2004 — CCR2-knockout vs wild-type mice after femoral artery ligation
| Heil M et al. Collateral artery growth (arteriogenesis) after experimental arterial
occlusion is impaired in mice lacking CC-chemokine receptor-2. Circ Res.
2004;94(5):671-7. CCR2-deficient mice achieved
only 47% of the blood flow recovery of wild-type controls (ratio 0.21 vs 0.45) after
arterial occlusion, with dramatically reduced monocyte/macrophage infiltration into
perivascular collateral spaces. This establishes that high CCL2-CCR2 signaling benefits
collateral vessel remodeling in ischemia — a different dimension of the same inflammatory axis
that drives atherosclerosis in the non-ischemic arterial wall.

At the clinical level,
Gonzalez-Quesada & Frangogiannis 2009 | Gonzalez-Quesada C, Frangogiannis NG. Monocyte
chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes. Curr Atheroscler
Rep. 2009;11(2):131-8 reviewed evidence that
circulating MCP-1 levels provide independent prognostic information in acute coronary syndromes
— higher levels correlating with greater atherosclerotic plaque burden and worse post-infarction
remodeling outcomes.

Practical Actions

The rs13900 variant has no independent clinical guidelines or ClinVar classification — its
clinical relevance derives from its perfect linkage disequilibrium with the better-studied
rs1024611G promoter variant. Carriers of the CT or TT genotype share the high-output CCL2
haplotype and the associated inflammatory cardiovascular risk profile. For TT homozygotes,
the priority is the same set of inflammatory and lipid biomarkers that characterize rs1024611
GG carriers: hs-CRP, lipoprotein(a), and blood pressure monitoring are the most genotype-relevant
tests to prioritize in cardiovascular risk assessment.

Interactions

rs13900 and rs1024611 are in perfect linkage disequilibrium (D'=1.0, r²≈1.0) in European
populations and act as proxies for each other. The rs1024611G allele increases CCL2 transcription
(promoter effect), while rs13900T extends mRNA half-life and improves translation efficiency
(post-transcriptional effect). Together they amplify CCL2 output through two distinct mechanisms.
Individuals who carry both the rs1024611 G allele and rs13900 T allele on the same haplotype —
which is essentially all carriers of either, given their perfect LD — have compounded transcriptional
and post-transcriptional amplification of CCL2/MCP-1.

The CCR2 receptor variant rs1799864 (V64I) modulates the downstream signaling efficiency of
whatever CCL2 is produced. While this receptor variant showed no independent CAD association
in the Wang 2011 meta-analysis, its interaction with the high-output CCL2 haplotype remains
biologically plausible and warrants attention.